Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? / Pouillon, L., Van Stappen, J., Bossuyt, P., Danese, S., Peyrin-Biroulet, L.. - In: BAILLIERE'S BEST PRACTICE & RESEARCH. CLINICAL GASTROENTEROLOGY. - ISSN 1521-6918. - 32-33:(2018), pp. 17-25. [10.1016/j.bpg.2018.05.006]
Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
Danese S;
2018-01-01
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis.pdf
solo gestori archivio
Dimensione
683.35 kB
Formato
Adobe PDF
|
683.35 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
